|1.||Emery, Paul: 19 articles (01/2015 - 06/2002)|
|2.||Becker, Jean-Claude: 16 articles (03/2015 - 06/2002)|
|3.||Westhovens, Rene: 15 articles (03/2015 - 06/2006)|
|4.||Li, Tracy: 15 articles (10/2011 - 08/2005)|
|5.||Kremer, Joel M: 11 articles (02/2015 - 06/2005)|
|6.||Schiff, Michael: 10 articles (01/2014 - 09/2005)|
|7.||Aranda, Richard: 10 articles (08/2012 - 08/2005)|
|8.||Abud-Mendoza, Carlos: 9 articles (10/2015 - 06/2006)|
|9.||Becker, J-C: 9 articles (11/2011 - 02/2007)|
|10.||Russell, Anthony S: 8 articles (07/2014 - 04/2006)|
01/01/2014 - "Intravenous abatacept has good clinical efficacy with an acceptably low toxicity profile in rheumatoid arthritis, but the subcutaneous mode of delivery has only recently become available. "
01/01/2010 - "In clinical trials, abatacept is effective in treating the signs and symptoms of rheumatoid arthritis as well as in inhibiting structural damage. "
05/01/2011 - "Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data."
11/01/2006 - "Abatacept, a newly approved agent for the treatment of rheumatoid arthritis, has shown promising results in patients who have had an inadequate response to other treatment modalities. "
04/01/2015 - "Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan."
09/01/2005 - "Patients with severe arthritis who took abatacept with at least one other disease-modifying antirheumatic drug in six and 12-month clinical trials demonstrated statistically significant improvement in tender, swollen joints and other clinical measures compared with placebo. "
12/01/2011 - "A post-hoc analysis suggests however that abatacept may be beneficial in lupus patients with arthritis however, it will probably never be approved for that indication. "
06/01/2013 - "Abatacept is a biologic developed for inflammatory arthritis but has shown promise in SLE. "
01/01/2012 - "After 2 months, he was registered on the Phase III trial of abatacept in Japan because of worsening of arthritis. "
01/01/2015 - "These results show that abatacept decreased disease activity in the absence of CD4(+) T cells, indicating that the mode of action of abatacept in established arthritis does not depend entirely on its effects on CD4(+) T cell activation."
|3.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
06/01/2010 - "Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis."
08/02/2008 - "We aimed to assess the safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous treatments. "
08/02/2008 - "Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial."
10/01/2015 - "Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years."
11/01/2010 - "To assess health-related quality of life (HRQOL) in abatacept-treated children/adolescents with juvenile idiopathic arthritis (JIA). "
10/01/2015 - "The aim of our study is to describe the role of abatacept in achieving remission in patients with idiopathic uveitis previously treated with TNF-α antagonists, and to assess how long abatacept efficacy is maintained during follow-up. "
10/01/2015 - "Three patients affected with chronic idiopathic uveitis, who have been treated with abatacept due to loss of efficacy of TNF-α antagonists, were reviewed. "
10/01/2015 - "Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series."
11/01/2015 - "CTLA4-Ig may have therapeutic effects on human chronic uveitis. "
10/01/2015 - "Our small case series seems to suggest abatacept to be a promising therapy in children affected with chronic idiopathic uveitis not adequately controlled by TNF-α antagonists."
09/01/2014 - "In this study, the effects of abatacept on the size and function of circulating B and T cells in RA patients not responding to anti-tumour necrosis factor (TNF)-α have been analysed, with the aim of identifying immunological parameters helpful to choosing suitable tailored therapies. "
06/01/2011 - "In this prospective open-label pilot study, abatacept (10 mg/kg) was administered intravenously on days 1, 15, 29 and every 28 days thereafter up to week 24 in 15 tumour necrosis factor α (TNFα)-inhibitor naive patients (group 1) and 15 patients with inadequate response to TNFα inhibitors (group 2) with active AS. "
01/01/2009 - "Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition."
03/01/2000 - "Necrosis was extensive in control rats, whereas CTLA4-Ig treated animals had grafts with at least some preserved villus morphology and no necrotic tissue. "
11/01/2009 - "The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial."
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|6.||Antirheumatic Agents (DMARD)
|10.||TNFR-Fc fusion protein (etanercept)
|2.||Transplantation (Transplant Recipients)